Outer membrane alterations were characterized in spontaneous mutants of the Erwinia chrysanthemi 3937jRH, which were selected for resistance to bacteriophage phi EC2. All but one of the mutants analyzed were affected in their lipopolysaccharide (LPS) structure, lacking the entire heterogeneous region of apparent high molecular weight present in the wild-type E. chrysanthemi LPS. At least two 3937jRH mutants, one selected as phi EC2 resistant (RH6065) and the other previously selected (D. Expert and A. Toussaint, J. Bacteriol. 163:221-227, 1985) as bacteriocin resistant (R1456), were cross-resistant to bacteriophage Mu and had rough LPSs with an altered core structure. Two phi EC2r mutants (RH6053 and RH6065) were most severely affected in their outer membrane integrity and also lost their virulence on saintpaulia plants, although they still possessed normal extracellular levels of pectinolytic and cellulolytic activities. The two Mur mutants RH6065 and R1456 were also able to induce systemic resistance in the challenged plant. All the other phi EC2r mutants retained the virulence of 393jRH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC213701 | PMC |
| http://dx.doi.org/10.1128/jb.169.9.4011-4017.1987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
L-Asparaginase from Lachancea Thermotolerans: Effect of Lys99Ala on Enzyme Performance and in vitro Antileukemic Efficacy.
Biotechnol J
November 2024
Department of Bioengineering, Gebze Technical University, Gebze, Kocaeli, Türkiye.
Article Synopsis
- L-asparaginases are enzymes that convert L-asparagine into L-aspartic acid and ammonia, and they are important in the pharmaceutical industry, particularly for cancer treatments.
- Scientists are exploring yeast-derived L-asparaginases as an alternative to bacterial ones, which can cause adverse immune responses.
- The study focuses on a specific yeast enzyme, Lachancea thermotolerans, demonstrating that a mutant form of this enzyme shows increased activity and significant antileukemic potential compared to commercial bacterial versions.
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report.
Ther Adv Hematol
September 2024
Haematology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Polyethylene-glycolated -derived l-asparaginase (pegaspargase, pASP) is an essential component of paediatric-inspired regimens for the treatment of acute lymphoblastic leukaemia/lymphoma; nonetheless, is characterised by severe and potentially life-threatening toxicities, such as hypertriglyceridemia. Grades 3-4 events have been reported in ~1%-18% of paediatric patients and in sparse reports in adults. There is limited evidence on the safety of asparaginase rechallenge in patients experiencing severe pASP-related hypertriglyceridemia.
View Article and Find Full Text PDFLong-acting Erwinia chrysanthemi, Pegcrisantaspase, induces alternate amino acid biosynthetic pathways in a preclinical model of pancreatic ductal adenocarcinoma.
Cancer Metab
June 2024
Department of Medical Oncology, West Virginia University School of Medicine, Morgantown, WV, USA.
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease without meaningful therapeutic options beyond the first salvage therapy. Targeting PDAC metabolism through amino acid restriction has emerged as a promising new strategy, with asparaginases, enzymes that deplete plasma glutamine and asparagine, reaching clinical trials. In this study, we investigated the anti-PDAC activity of the asparaginase formulation Pegcrisantaspase (PegC) alone and in combination with standard-of-care chemotherapeutics.
View Article and Find Full Text PDFA Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from .
Int J Mol Sci
April 2024
Laboratory of Natural Products, Department of Pharmacy, Faculty of Health Sciences, University of Brasilia, Brasilia 70910-900, Brazil.
L-asparaginase is an essential drug used to treat acute lymphoid leukemia (ALL), a cancer of high prevalence in children. Several adverse reactions associated with L-asparaginase have been observed, mainly caused by immunogenicity and allergenicity. Some strategies have been adopted, such as searching for new microorganisms that produce the enzyme and applying protein engineering.
View Article and Find Full Text PDFDesirable L-asparaginases for treating cancer and current research trends.
Front Microbiol
March 2024
Department of Industrial Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.
Amino acid depletion therapy is a promising approach for cancer treatment. It exploits the differences in the metabolic processes between healthy and cancerous cells. Certain microbial enzymes induce cancer cell apoptosis by removing essential amino acids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!